Conformis Announces Achievement of Third Milestone Under Development and License Agreements
April 22, 2021 16:30 ET
|
Conformis, Inc.
BILLERICA, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it received 510(k) clearance by the U.S. Food and Drug Administration for patient-specific...
Conformis Announces Achievement of Second Milestone Under Development and License Agreements
August 20, 2020 07:30 ET
|
Conformis, Inc.
BILLERICA, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it completed the second of three milestones pursuant to the License Agreement and Development...
Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference
February 05, 2019 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
December 20, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will...
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel
December 17, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
December 06, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices,...
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
December 04, 2018 07:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is...
Ascom announces partnership with Stryker to deliver Stryker iBed wireless notifications to clinicians to target fall prevention
August 28, 2018 08:00 ET
|
Ascom Holding AG
BAAR, Switzerland, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Ascom (SWX:ASCN.SW), the global solutions provider focused on healthcare ICT and mobile workflow solutions, announced a new North American...
Stryker R&D Executive to Speak at Clinical Research Conference on December 4, 2013
November 26, 2013 09:01 ET
|
Clinical Research in Georgia
ATLANTA, GA--(Marketwired - Nov 26, 2013) - Marc Long, PhD, Senior Director, Technology and Innovation, Stryker Orthobiologics, will provide a keynote address at the second annual Clinical Research...
Dean Goetz Lawyer and John Gomez Secure $8.34 Million for Plaintiff Loren Kransky in DePuy ASP Hip Lawsuit
August 02, 2013 16:26 ET
|
Dean Goetz Law Firm
SAN DIEGO, CA--(Marketwired - Aug 2, 2013) - Due to a defective DePuy ASR XL hip implant, Loren Kransky was given less than six months to live. The amounts of cobalt and chromium metal levels in...